Concerns about the development of adverse effects of chronic INI treatment stimulated research on alternative PD treatment approaches with Glucagon-like Peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Here, DPP4 is linked to Parkinson disease.